Participating Faculty

Supplements and Featured Publications, New Approaches for the Management and Treatment of Migraine, Volume 11, Issue 2 Suppl

The American Journal of Managed Care

This supplement to contains information about new approaches for the management and treatment of migraine.

Faculty

Andrew Blumenfeld, MDDirector

Scripps Memorial Hospital-Encinitas

President

Battle Ground, Washington

Gary M. Owens, MD

Medical Management and Policy

Philadelphia, Pennsylvania

Disclosure Statement

In accordance with the ACCME and the ACPE, participants for this activity have completed a conflict-of-interest statement.

In compliance with the Health Insurance Portability and Accountability Act standards, no presentations in this CME/CE activity shall disclose the names or other identifiers of patients referenced without a signed waiver from the identified patient.

The American Journal of Managed Care

It is the policy of to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

This participant has declared the following relationships with pharmaceutical organizations:

Andrew Blumenfeld, MD

Research/Grant Support From/Advisory Board For:

  • Allergan

Research Support From:

  • Medtronics

Speakers

' Bureau For:

  • Ortho-McNeil GlaxoSmithKline

This participant reports no relationships with pharmaceutical organizations:

  • Gary M. Owens, MD

Disclosure information for Lawrence D. Goldberg, MD, MBA, was not available at the time of publication.

NOTE: This supplement contains information about off-label usage of botulinum toxin for migraine prophylaxis. The discussion of botulinum toxin should not be construed as an endorsement of this therapeutic modality or of its manufacturer. The manufacturer is seeking approval from the US Food and Drug Administration (FDA) for the use of botulinum toxin for migraine pain. Currently, the drug is in phase 3 of clinical trials.

This supplement also includes discussion of epilepsy drugs. The reader should be aware that the FDA has recently requested manufacturers of epilepsy drugs to reexamine their clinical trial data in response to claims that such medications may increase the risk of suicide in some patients.